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Background  and purpose:  Brachial-ankle  pulse  wave  velocity  (baPWV)  and  ratio  of plasma  eicosapen-
taenoic  acid  to  arachidonic  acid  (EPA/AA  ratio)  are  surrogate  markers  for coronary  artery  disease  (CAD).
We aimed  to  evaluate  the  effects  of a ﬁsh-based  diet and  administration  of  EPA on  baPWV  and  plasma
EPA/AA  ratio.
Methods  and  results:  The  changes  in baPWV  and  plasma  EPA/AA  ratio were  compared  before  and  after  a
6-month  ﬁsh-based  diet  in  191  patients  with cardiovascular  risk  factors.  A ﬁsh-based  diet resulted  in  sig-
niﬁcant  increment  of plasma  EPA/AA  ratio  (0.40  ±  0.18  vs.  0.49  ± 0.27,  p < 0.001),  with  baPWV  remaining
unchanged.  Multivariate  analysis  revealed  that  systolic  blood  pressure  (SBP)  (6-month  SBP-baseline  SBP)
and CAD  were  positively  associated  with  increased  baPWV  (CAD:  odds  ratio  = 2.040,  p =  0.0436,  SPB:
odds  ratio = 1.056,  p =  0.0003).  When  the patients  were  divided  into  three  groups:  CAD,  low-risk,  and
high-risk  with  no prior  history  of CAD  according  to the number  of risk  factors  at  baseline,  comparison
among  the  three  groups  disclosed  an  inter-group  difference  in  the  magnitude  of change  in  baPWV  (low-
risk: −35  ±  164  cm/s,  high-risk:  −14 ± 190 cm/s,  CAD:  39  ± 164  cm/s,  p = 0.0071  for  trend).  In  191 patients
who had  received  a 6-month  ﬁsh-based  diet,  21 patients  (primarily  CAD  patients)  sequentially  received
high  purity  EPA  (1800  mg/day)  for 6 months.  It resulted  in marked  increment  of  plasma  EPA/AA ratio
(0.65  ± 0.57  vs. 1.19  ± 0.46,  p  < 0.001),  accompanied  by  signiﬁcant  reduction  in baPWV  (1968  ± 344 cm/s
vs.  1829  ± 344  cm/s,  p  = 0.0061).  There  was  a signiﬁcant  negative  correlation  between  changes  in baPWV
and  changes  in  plasma  EPA/AA  ratio  in patients  with a  ﬁsh-based  diet  and  sequential  administration  of
EPA (r = −0.446,  p  = 0.017).
Conclusion:  A ﬁsh-based  diet  was  effective  against  increased  baPWV  only  in low-risk  patients,  with  slight
increment  of  plasma  EPA/AA.  In high-risk  patients  and  CAD  patients,  administration  of EPA  for  preventing
progression  of  baPWV  endorsed  the  validity  of  high  purity  EPA  administration  recommended  in  the
current  guidelines.
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Brachial-ankle pulse wave velocity (baPWV) which reﬂects arterial
stiffness serves as a predictor of the onset of cardiovascular events
in primary or secondary prevention [2,3].
As far as secondary prevention for patients with coronary artery
disease (CAD) is concerned, we may  say that the residual risk has
not yet been sufﬁciently suppressed [4]. Multi-faceted approaches
including glycemic control, blood pressure control, lipid lower-
ing with statin therapy [5], aspirin therapy, angiotensin-converting
enzyme inhibitors, and lifestyle modiﬁcations, now seem desirable
to reduce the residual risk in patients with CAD. Recently, close
attention has been paid to eicosapentaenoic acid (EPA), one of the
omega-3 polyunsaturated fatty acids (PUFA), that has been proven
to reduce the risk of major coronary events [6]. Research on EPA
vier Ltd. All rights reserved.
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ates back to the 1970s, when a study revealed that Inuit, liv-
ng in Greenland and ingesting seals or the like as the main diet,
ad a lower prevalence of cardiovascular disease than Caucasians,
ccompanied by a high plasma level of EPA [7]. Since then, reports
ave been published, demonstrating the effectiveness of multiple
mega-3 PUFA in preventing cardiovascular events, including sud-
en cardiac death [8,9]. Statins and omega-3 PUFA are the most
avorable lipid-lowering interventions with reduced risks of overall
nd cardiac mortality [9].
The addition of EPA to statin therapy provides further beneﬁts
n preventing cardiovascular events, mainly through cholesterol-
ndependent mechanisms, in patients with hypercholesterolemia,
specially for the secondary prevention of CAD [6]. Therefore, the
uidelines published in 2012 by the Japan Atherosclerosis Soci-
ty state that administration of EPA in addition to statin deserves
onsideration for high-risk patients with dyslipidemia [10].
EPA has anti-atherosclerotic effects and reduces baPWV, a
arker for arterial stiffness [11]. EPA is taken up into the cell
embrane in the form of phospholipid, resulting in formation of
iologically active substances [prostaglandin (PG) I3, thromboxane
3, and leukotriene B5). EPA is thus expected to exert vasopro-
ective activity. On the other hand, PG, formed from arachidonic
cid (AA), is known to induce vascular smooth muscle contrac-
ion, thrombus formation, and inﬂammation, thus antagonizing the
G formed from EPA [12]. The ratio of EPA to AA (EPA/AA ratio)
n cell membrane and plasma serves as an overall marker of the
ctions of multiple types of PG conﬂicting with each other. There is
 recent trend toward utilization of plasma EPA/AA ratio as “a new
isk marker” for cardiovascular disease [13,14].
Not much has been done to clarify the effects of a ﬁsh-based diet
n baPWV from the viewpoint of plasma EPA/AA ratio.
This study was undertaken to elucidate the factors associated
ith increased baPWV, and to verify whether a ﬁsh-based diet
nd sequential treatment of pure EPA affected baPWV and plasma
PA/AA ratio in patients with cardiovascular risk factors.
ethods
tudy populationWe  assessed a consecutive series of 257 outpatients with car-
iovascular risk factors managed for eligibility (Fig. 1). Inclusion
riteria were CAD, hypertension, dyslipidemia, and diabetes. Exclu-
ion criteria were therapy of EPA, peripheral artery disease, aortic
Pa nts assessed for eligibility (n=257)
Excluded (n=55):
Peripheral artery disease (n=5) A alve disease (n=2)
) A
vascular gra ) Obs rdiomyopathy (n=1)
At Therapy of EPA (n=10)
Pa nts allocated to a 6-month fish based diet (n=202)
Excluded (n=11):
tudy
Complete follow-up (n=191)
Pa nts allocated to a  with pure EPA (n=21)
Complete follow-up (n=21)
Fig. 1. Flow chart of the study population. EPA, eicosapentaenoic acid.iology 63 (2014) 211–217
valve disease, aortic aneurysm, aortic dissection, artiﬁcial vascu-
lar graft, obstructive cardiomyopathy, and atrial ﬁbrillation. We
excluded medication changes during the study. We enrolled 191
patients in the present study, with informed consent and the ethics
committee approval.
Baseline data measurements
Blood low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), triglyceride (TG), creatinine (Cr),
HbA1c (Japan Diabetes Society), and plasma PUFA [EPA, AA, and
docosahexaenoic acid (DHA)] were measured. Systolic blood pres-
sure (SBP), baPWV, and ankle/brachial index (ABI) were measured
at right brachial and both ankles with a blood pressure pulse wave
testing device (BP-203RPE II form PWV/ABI; Omron Healthcare Co.,
Ltd, Tokyo, Japan), which has been described detail previously [15].
SBP and baPWV of the side with ABI less than 0.9 were excluded and
the higher baPWV was  included. Carotid maximum intima-media
thickness (IMT) was  measured by ultrasonography.
Fish-based diet and administration of pure EPA
The protocol of a ﬁsh-based diet consisted of a 6-month dietary
intervention period. Fish-based diet was  assessed at baseline with
self-administered food-frequency questionnaires (FFQ). The dieti-
cian instructed each patient and his/her family members about the
daily intake of ﬁsh by a food model. During the ﬁsh-base inter-
vention period, the study subjects were instructed to eat no less
than 1.0 g/day omega-3 PUFA derived from ﬁsh which is the recom-
mended dose for CAD patients by the American Heart Association
(AHA) [16]. The adherence to a ﬁsh-based diet was  evaluated at the
end of a 6-month period by a dietician.
After a 6-month ﬁsh-based diet, subsequent oral administration
of pure EPA (1800 mg/day) for 6 months was  provided to CAD and
high-risk patients with dyslipidemia according to Japan Atheroscle-
rosis Society guidelines [10].
BaPWV and plasma PUFA were measured at the end of the
6-month ﬁsh-based diet and at the end of 6-month oral admin-
istration of pure EPA.
Deﬁnitions
Estimated glomerular ﬁltration rate (estimated GFR,
mL/min/1.73 m2) was calculated using the equation given below.
GFR(male) = 194 ∗ serumCr−1.094 ∗ age−0.287
GFR(female) = GFR(male) ∗ 0.739
Left ventricular hypertrophy (LVH) was  deﬁned as thickness
≥13 mm by echocardiography.
Changes from baseline to those after the 6-month ﬁsh-based
diet are abbreviated as .
Factors determining baPWV were explored, by dividing the
patients into two  groups, increased baPWV (baPWV > 0 cm/s)
and decreased baPWV (baPWV≤0 cm/s), and comparing baseline
risk factors, percentage of low-risk/high-risk/CAD, and concomi-
tant drugs between the two groups.
The patients were divided into CAD patients (CAD) and non-CAD
patients at baseline. We  deﬁned age ≥45 years (male) or ≥55 years
(female), hypertension, diabetes, and HDL-C <40 mg/dl, as risk fac-
tors. The non-CAD group was  subdivided into high-risk (possessing
3 or more major risk factors) and low-risk (possessing 2 or fewer
major risk factors) according to the number of risk factors. baPWV
was compared among the three groups that are CAD, high-risk and
low-risk.
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vs.1882 ± 404 cm/s, p = 0.7350, CAD: 1825 ± 351 cm/s vs.
1864 ± 349 cm/s, p = 0.0686). Among the three groups, baPWV
had evident inter-group differences (low-risk: −35 ± 164 cm/s,Y. Fukuoka et al. / Journal o
tatistical analysis
Data are expressed as mean ± standard deviation or number of
atients. Unpaired Student’s t-test or paired Student’s t-test was
sed for comparison of data between the two groups. Chi-square
est or Bonferroni’s multiple comparison test after one-way anal-
sis of variance was employed for comparison among the three
roups. Step-wise logistic regression analysis was  carried out to
dentify risk factors associated with increased baPWV during the 6-
onth ﬁsh-based diet. A value of p < 0.05 (two-tailed) was  regarded
s statistically signiﬁcant. Pearson correlation coefﬁcients were cal-
ulated to investigate the association among changes in baPWV and
hanges in plasma EPA/AA ratio.
esults
aseline characteristics of the study population
Atherosclerosis tended to be severe, with the mean baPWV
eing 1824 ± 366 cm/s and the mean maximum-IMT being
.00 ± 1.03 mm (Table 1). Eighty-nine patients (46.6%) were receiv-
ng oral statin therapy, with lipids being controlled relatively well
LDL-C 106.7 ± 29.3 mg/dl, LDL/HDL-C ratio 1.94 ± 0.69). The mean
lasma EPA was 75.6 ± 38.4 g/ml, and the mean plasma EPA/AA
atio was 0.42 ± 0.19 g/ml.
ffects of a 6-month ﬁsh-based dietThe ratio of patients with good adherence to 1.0 g/day
ntake of omega-3 PUFA 6-month ﬁsh-based diet was 58%. SBP
as signiﬁcantly reduced, while baPWV remained unchanged,
able 1
aseline characteristics of the study population.
N 191
Age (years) 70.3 ± 10.4
Male (%) 110 (57.6%)
Body mass index (kg/m2) 24.0 ± 3.5
Hypertension (%) 173 (90.6%)
Systolic blood pressure (mmHg) 133.8 ± 15.2
Pulse rate (bpm) 64.1 ± 10.5
Diabetes (%) 34 (17.8%)
HbA1c (%) 5.5 ± 0.5
Dyslipidemia (%) 74 (38.7%)
LDL-C (mg/dL) 106.7 ± 29.3
HDL-C (mg/dL) 58.5 ± 17.3
LDL-C/HDL-C ratio 1.94 ± 0.69
Triglyceride (mg/dL) 110.6 ± 48.8
EPA (g/mL) 75.6 ± 38.4
DHA (g/mL) 167.8 ± 53.8
AA  (g/mL) 180.8 ± 45.1
EPA/AA ratio 0.42 ± 0.19
Estimated GFR (mL/min/1.73 m2) 64.1 ± 14.1
baPWV (cm/s) 1824 ± 366
Maximum IMT  (mm) 2.00 ± 1.03
Left ventricular hypertrophy (%) 105 (55.0%)
Low-risk patients with no prior history of CAD (%) b 106 (55.5%)
High-risk patients with no prior history of CAD (%) a 23 (12.0%)
CAD patients (%) 62 (32.5%)
Medication (%)
Statin 89 (46.6%)
RAS  inhibitors 125 (65.4%)
ata are number of patients (%) or mean ± SD. Hb, hemoglobin; LDL-C, low-density
ipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; EPA, eicosa-
entaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid; GFR, glomerular
ltration rate; baPWV, brachial-ankle pulse wave velocity; IMT, intima-media thick-
ess; CAD, coronary artery disease; RAS, renin–angiotensin system.
a Any three of the following: (1) older age (male 45, female 55), (2) hyperten-
ion, (3) diabetes, and (4) low levels of HDL-C (<40 mg/dL).
b Except for high-risk patients with no prior history of CAD.iology 63 (2014) 211–217 213
when measured after a ﬁsh-based diet (SBP: 133.8 ± 15.2 mmHg
vs. 130.9 ± 16.6 mmHg, p = 0.0014, baPWV: 1824 ± 366 cm/s vs.
1815 ± 354 cm/s, p = 0.4991).
Factors associated with increased baPWV
As compared to the decreased baPWV group (n = 99), the
increased baPWV group (n = 92) was lower in age, baPWV, and
percentage of low-risk cases, while being higher in HbA1c and per-
centage of CAD cases (Table 2). There were no signiﬁcant differences
in blood LDL-C, LDL-C/HDL-C ratio, TG, plasma EPA, DHA, or EPA/AA
ratio.
Multivariate analysis revealed that SBP and CAD were posi-
tively associated with increased baPWV (SPB: odds ratio = 1.056,
p = 0.0003, CAD: odds ratio = 2.040, p = 0.0436) (Table 3).
Effects of a 6-month ﬁsh-based diet on baPWV among the three
groups
Among the three groups: low-risk (n = 106), high-risk (n = 23),
and CAD (n = 62), baPWV signiﬁcantly decreased in the low-
risk group after a 6-month ﬁsh-based diet (1807 ± 370 cm/s
vs.1773 ± 344 cm/s, p = 0.0315), but did not decrease in
the high-risk and CAD groups (high-risk: 1896 ± 369 cm/shigh-risk: −14 ±190 cm/s, CAD: 39 ± 164 cm/s, p = 0.0071 for
Table 2
Baseline risks for increased baPWV during a 6-month ﬁsh-based diet.
BaPWV: >0 BaPWV: 0 p-Valuea
N 92 99
BaPWV (cm/s) 121 ± 11 −128 ± 115 <0.0001*
Age (years) 68.1 ± 10.6 72.3 ± 9.8 0.0050*
Male (%) 59 (64.1%) 51 (50.5%) 0.0779
Body mass index (kg/m2) 24.3 ± 3.9 23.8 ± 3.0 0.3128
Hypertension (%) 83 (90.2%) 90 (90.9%) 0.8701
Systolic blood pressure (mmHg) 133.2 ± 13.9 134.4 ± 16.4 0.5889
Pulse rate (bpm) 63.7 ± 10.2 64.4 ± 10.8 0.6331
Diabetes (%) 18 (19.6%) 16 (16.2%) 0.5389
HbA1c (%) 5.6 ± 0.6 5.4 ± 0.4 0.0477*
Dyslipidemia (%) 39 (42.4%) 35 (35.4%) 0.3185
LDL-C (mg/dL) 102.8 ± 27.9 110.2 ± 30.3 0.0818
HDL-C (mg/dL) 58.7 ± 17.4 58.4 ± 17.4 0.9049
LDL-C/HDL-C ratio 1.88 ± 0.73 2.00 ± 0.64 0.2397
Triglyceride (mg/dL) 116.4 ± 54.6 105.1 ± 42.2 0.1111
EPA (g/mL) 74.4 ± 35.3 76.8 ± 41.1 0.6717
DHA (g/mL) 165.3 ± 50.0 170.0 ± 57.2 0.5445
AA  (g/mL) 181.5 ± 49.7 180.2 ± 40.6 0.8534
EPA/AA ratio 0.42 ± 0.18 0.43 ± 0.20 0.7121
Estimated GFR (mL/min/1.73 m2) 64.8 ± 13.1 63.5 ± 15.1 0.5083
baPWV (cm/s) 1732 ± 309 1909 ± 395 0.0007*
Maximum IMT  (mm) 2.06 ± 1.23 1.95 ± 0.80 0.4749
Left  ventricular hypertrophy (%) 9 (53.3%) 6 (56.6%) 0.6465
Low-risk with no prior history of
CAD (%)
4 (47.8%) 2 (62.6%) 0.0397*
High-risk with no prior history of
CAD (%)
0 (10.9%) 3 (13.1%) 0.6313
CAD patients (%) 8 (41.3%) 4 (24.2%) 0.0119*
Medication
Statin (%) 9 (53.3%) 0 (40.4%) 0.0751
RAS inhibitors (%) 2 (67.4%) 3 (63.6%) 0.5856
Data are number of patients (%) or mean ± SD. Hb, hemoglobin; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; EPA, eicosa-
pentaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid; GFR, glomerular
ﬁltration rate; baPWV, brachial-ankle pulse wave velocity; IMT, intima-media thick-
ness; CAD, coronary artery disease; RAS, renin–angiotensin system.
a Unpaired Student’s t-test or -test.
* p < 0.05.
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Table 3
Multivariate logistic regression analysis to identify factors associated with increased
baPWV during a 6-month ﬁsh-based diet.
Variables Odds ratio (95% conﬁdence interval) p-Value
Age 0.970 (0.934–1.007) 0.1122
SBP  1.056 (1.026–1.088) 0.0003*
CAD 2.040 (1.021–4.079) 0.0436*
Baseline HbA1c 1.580 (0.807–3.093) 0.1817
Baseline triglyceride 1.006 (0.999–1.014) 0.0787
Baseline PWV  0.999 (0.998–1.000) 0.1246
Stepwise logistic regression analysis was performed to evaluate risk factors for
increased baPWV. baPWV, brachial-ankle pulse wave velocity; SBP, systolic blood
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cressure; CAD, coronary artery disease; Hb, hemoglobin.
* p < 0.05.
rend) (Fig. 2), and for SBP and ratio of patients with good adher-
nce, there were no signiﬁcant differences (p = 0.2869, p = 0.4799,
espectively).
In Table 4, the percentage of patients receiving statin therapy
n the CAD group was higher than those in the other two groups,
nd LDL-C in the CAD group was lower than those in the other two
roups. There were no signiﬁcant differences in age, body mass
ndex, SBP, plasma EPA/AA ratio, eGFR, baPWV, and maximum-IMT.
equential treatment with pure EPATwenty one patients with CAD (n = 18) and high-risk (n = 3)
ere allocated to a sequential treatment with pure EPA, accom-
anied by signiﬁcant reduction of baPWV (1968 ± 344 cm/s vs.
829 ± 344 cm/s, p = 0.0061) (Fig. 3).
able 4
aseline characteristics of CAD patients, high-risk or low-risk patients with no prior histo
CAD patients 
N 62 
Age  (years) 70.7 ± 9.0 
Male  (%) 47 (75.8%)##
Body mass index (kg/m2) 23.5 ± 3.5 
Hypertension (%) 52 (83.9%)
Systolic blood pressure (mmHg) 131.6 ± 16.7 
Pulse  rate (bpm) 61.4 ± 9.6#
Diabetes (%) 19 (30.6%)##,§§
HbA1c (%) 5.7 ± 0.6##
Dyslipidemia (%) 26 (41.9%) 
LDL-C  (mg/dL) 87.2 ± 20.4 
HDL-C (mg/dL) 51.0 ± 12.7##
LDL-C/HDL-C ratio 1.78 ± 0.47§§
Triglyceride (mg/dL) 107.9 ± 48.0 
EPA  (g/mL) 72.1 ± 35.9 
DHA  (g/mL) 149.9 ± 53.1 
AA (g/mL) 164.0 ± 44.8##
EPA/AA ratio 0.44 ± 0.18 
Estimated GFR (mL/min/1.73 m2) 61.6 ± 13.1 
baPWV (cm/s) 1825 ± 351 
Maximum IMT  (mm)  2.21 ± 0.85 
Left  ventricular hypertrophy (%) 40 (64.5%) 
Medication (%) ewfe 
Statin  49 (79.0%)##,§§
RAS inhibitors 36 (58.1%) 
ata are number of patients (%) or mean ± SD. Hb, hemoglobin; LDL-C, low-density lipoprot
cid; DHA, docosahexaenoic acid; AA, arachidonic acid; GFR, glomerular ﬁltration rate;
oronary artery disease; RAS, renin–angiotensin system. ‡p < 0.05.
a One-way ANOVA or 2-test.
* p < 0.05.
# p < 0.05.
## p < 0.01 (vs. low-risk).
§ p < 0.05.
§§ p < 0.01 (vs. high-risk).
‡‡ p < 0.01 (vs. CAD).groups for CAD (p = 0.0071 for trend). baPWV, brachial-ankle pulse wave velocity;
CAD, coronary artery disease.
Assessment of plasma fatty acid
Baseline data measurements
In the FFQ, plasma EPA, DHA and EPA/AA ratio in patients withfrequency of ﬁsh intake 5 servings per week (29.7%) were higher
than those with frequency of ﬁsh intake <5 servings per week
(70.3%) (EPA: 92.1 ± 52.5 g/ml vs. 67.7 ± 34.4 g/ml, p = 0.0181,
ry of CAD Patients with no prior history of CAD.
Patients with no history of CAD p-Valuea
High-risk Low-risk
23 106
72.3 ± 9.4 69.6 ± 11.3 0.4931
16 (69.6%)# 47 (44.3%) 0.0002*
25.4 ± 4.6 24.0 ± 3.1 0.0701
22 (95.7%) 99 (93.4%) 0.0843
135.8 ± 12.2 134.7 ± 14.9 0.3638
63.7 ± 10.1 65.7 ± 10.8 0.0375*
15 (65.2%)## 0 (0%) <0.0001*
5.8 ± 0.6## 5.3 ± 0.3 <0.0001*
12 (52.2%) 36 (34.0%) 0.2192
111.0 ± 22.6‡‡ 117.1 ± 29.4‡‡ <0.0001*
50.8 ± 18.7## 64.6 ± 17.1 <0.0001*
2.39 ± 0.75 1.94 ± 0.74§ 0.0012*
116.5 ± 49.1 110.8 ± 49.5 0.7669
74.5 ± 35.8 77.9 ± 40.4 0.6296
170.4 ± 61.9 177.6 ± 50.1‡‡ 0.0005*
168.5 ± 33.1# 193.3 ± 43.9 0.0001*
0.44 ± 0.18 0.41 ± 0.20 0.5403
68.1 ± 14.0 64.7 ± 14.6 0.1407
1896 ± 396 1807 ± 370 0.5781
1.96 ± 0.78 1.89 ± 1.15 0.1479
13 (56.5%) 52 (49.1%) 0.1494
fsf fefef gegrer
9 (39.1%) 31 (29.2%) <0.0001*
17 (73.9%) 72 (67.9%) 0.285
ein cholesterol; HDL-C, high-density lipoprotein cholesterol; EPA, eicosapentaenoic
 baPWV, brachial-ankle pulse wave velocity; IMT, intima-media thickness; CAD,
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Fig. 3. Serial changes in brachial-ankle PWV  in CAD patients and high-risk patients
with  no prior history of CAD. Open cycles represent means of each point. There
was  a signiﬁcant difference between the groups as determined by one-way ANOVA
(
E
D
r
D
E
p
d
T

p
ﬁsh-based diet and sequential administration of EPA (r = −0.446,
p = 0.017) (Fig. 4).
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Fig. 4. Relationship between changes in baPWV and changes in EPA/AA ratio after a
6-month ﬁsh-based diet and a 6-month sequential treatment with pure EPA. There
was a signiﬁcant negative correlation between changes in baPWV and changes in
plasma EPA/AA ratio [Pearson’s correlation coefﬁcient (r) = −0.446, p = 0.017]. Open
T
C
D
#F5.8367, p = 0.0060). PWV, pulse wave velocity; CAD, coronary artery disease;
PA, eicosapentaenoic acid.
HA: 183.5 ± 59.6 g/ml vs. 160.5 ± 49.0 g/ml, p = 0.0360, EPA/AA
atio: 0.49 ± 0.24 vs. 0.38 ± 0.18, p = 0.0281).
ata measurements at end of 6-month ﬁsh-based diet
A ﬁsh-based diet resulted in signiﬁcant increment of plasma
PA and EPA/AA ratio (EPA: 70.3 ± 36.6 g/ml vs. 88.2 ± 50.4 g/ml,
 < 0.001, EPA/AA ratio: 0.40 ± 0.18 vs. 0.49 ± 0.27, p < 0.001), but
id not result in signiﬁcant increment of plasma DHA (Table 5).
here was no signiﬁcant correlation between baPWV and
plasma EPA/AA ratio in patients with a ﬁsh-based diet (r = −0.13,
 = 0.083).
able 5
hanges in plasma fatty acids and its ratio to arachidonic acid during a 6-month ﬁsh-base
Baseline After a 6-month ﬁsh-based diet 
A 6-month ﬁsh-based diet
All patients
EPA (g/mL) 70.3 ± 36.6 88.2 ± 50.4***
DHA  (g/mL) 160.0 ± 52.4 157.9 ± 51.5 
AA  (g/mL) 177.1 ± 47.4 183.1 ± 47.5*
EPA/AA ratio 0.40 ± 0.18 0.49 ± 0.27***
Low-risk patients with no prior history of CAD
EPA (g/mL) 71.0 ± 40.9 88.9 ± 51.9**
DHA  (g/mL) 170.4 ± 49.9 164.1 ± 52.9 
AA  (g/mL) 192.3 ± 47.5 188.4 ± 38.5 
EPA/AA ratio 0.37 ± 0.19 0.48 ± 0.27**
CAD  patients and high-risk patients with no prior history of CAD
EPA (g/mL) 69.8 ± 32.9 87.6 ± 49.6***
DHA  (g/mL) 151.4 ± 53.2 152.7 ± 50.2 
AA  (g/mL) 164.5 ± 43.7 178.8 ± 53.7***
EPA/AA ratio 0.43 ± 0.17 0.50 ± 0.27*
A  6-month ﬁsh-based diet and a 6-month sequential treatment with EPA
EPA (g/mL) 60.5 ± 28.2 106.9 ± 96.7 
DHA  (g/mL) 133.6 ± 50.3 136.4 ± 46.1 
AA  (g/mL) 163.2 ± 70.6 167.3 ± 65.5 
EPA/AA ratio 0.39 ± 0.18 0.65 ± 0.57 
ata are mean ± SD. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AA, arachid
a One-way ANOVA.
* p < 0.05.
** p < 0.01.
*** p < 0.001 vs. baseline.
## p < 0.01.
## p < 0.001 vs. after 6 months (Paired Student’s t-test or Bonferroni’s multiple test).iology 63 (2014) 211–217 215
Data measurements at end of a 6-month sequential treatment
with pure EPA
A sequential treatment with pure EPA resulted in marked incre-
ment of plasma EPA and EPA/AA ratio (EPA: 106.9 ± 96.7 g/mL
vs. 179.9 ± 65.7 g/mL, p < 0.01, EPA/AA ratio: 0.65 ± 0.57 vs.
1.19 ± 0.46, p < 0.001). There was a signiﬁcant negative correlation
between baPWV and plasma EPA/AA ratio in patients with adiamonds represent changes in baPWV and plasma EPA/AA ratio after a 6-month
ﬁsh-based diet, and closed diamonds represent changes in baPWV and plasma
EPA/AA ratio after a 6-month pure EPA use. baPWV, brachial-ankle pulse wave
velocity; EPA, eicosapentaenoic acid; AA, arachidonic acid.
d diet or 6-month EPA use.
After a 6-month ﬁsh-based diet and a 6-month
sequential treatment with EPA
p-Valuea
– –
– –
– –
– –
– –
– –
– –
– –
– –
– –
– –
– –
179.9 ± 65.7*** ,## <0.0001
140.7 ± 53.8 0.7404
158.7 ± 55.4 0.7121
1.19 ± 0.46*** ,### <0.0001
onic acid; CAD, coronary artery disease.
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iscussion
e  elucidated CAD as one factor associated with increased baPWV
The present study had favorable blood LDL-C levels, but was
ated as having progressive atherosclerosis with maximum-IMT
nd increased baPWV, which was more than 18.0 m/s  reported
redicting a major cardiovascular event in CAD [2]. Laurent et al.
eported that PWV  was signiﬁcantly associated with all-cause and
ardiovascular mortality, independent of previous cardiovascular
isease (CVD), age, and diabetes [17]. Yambe et al. demonstrated
hat increased baPWV relates not only to the parameters reﬂecting
therosclerosis, but also to those reﬂecting cardiac diastolic dys-
unction [18]. Although the mechanisms concerned with baPWV
or a clinical cardiovascular event remain unclear, it is important
ot only to lower SBP but also to reduce aortic stiffness, baPWV.
Omega-3 PUFA have not only an antiatherosclerotic effect,
ut also an anti-inﬂammatory effect [19] and a blood pressure-
owering effect such as decrease in 2.1 mmHg  of SBP by ﬁsh oil
20]. The effect of EPA in reducing baPWV is not mediated by its
nﬂuence on serum lipid level or SBP [21].
EPA doses achieving plasma EPA over 150 g/ml and plasma
PA/AA ratio over 0.75 were needed to prevent CVD events in
apanese patients with dyslipidemia [22]. We  focused on the rela-
ionship between the magnitude of change in baPWV as a surrogate
arker and the plasma EPA/AA ratio. In the present study, the
light increment less than 0.75 in EPA/AA ratio by the ﬁsh-based
iet was enough to decrease baPWV in low-risk patients, but it
as not enough to decrease baPWV in high-risk patients and CAD
atients, and the marked increment more than 0.75 in EPA/AA
atio by the sequential treatment with pure EPA was enough to
ecrease baPWV in high-risk patients and CAD patients. In this
ay, we clariﬁed a different effect on baPWV with the ﬁsh-based
iet and sequential treatment with pure EPA according to the risk
tratiﬁcation.
With regard to the quantity of effective omega-3 PUFA, involv-
ng people in Western countries having abnormal glucose tolerance
nd high risk for CVD events, it was shown that administration of
mega-3 PUFA 1000 mg  did not sufﬁciently suppress CVD events
23]. According to the JPHC Study, the risk for onset of CAD and
yocardial infarction was signiﬁcantly lower by 42% and 65%,
espectively in the group ingesting the largest amount of omega-3
UFA (2.1 g/day) than in the group ingesting the smallest amount
0.3 g/day) [24]. The goal of omega-3 PUFA intake for prevention of
VD events seem to be high in high-risk patients.
The prevention of cardiovascular events by the addition of pure
PA required more than 2 years [25]. Regarding the inﬂuence of
ong-term pure EPA administration on baPWV, Kuroki reported that
 signiﬁcant reduction in baPWV began to be seen 3 months after
he start of oral pure EPA administration and remained to be seen
t 18 months after the start [21]. Therefore, it is likely that more
ime is needed to see the change in baPWV with a ﬁsh-based diet
r EPA administration for prevention of CVD events.
The AHA issued a statement recommending intake of omega-
 PUFA for prevention of CAD in 2002. According to it, intake of
sh twice or more per week is recommended for individuals free
f CAD and intake of EPA and DHA (1 g/day) is recommended for
ndividuals having CAD [22]. The recommended amount of EPA and
HA intake, made public by the Ministry of Health, Labor and Wel-
are in Japan, is 2 g/day for healthy individuals [26]. Although this
evel of EPA and DHA intake potentially can be attained through
sh consumption, the requisite amount of ﬁsh intake may  be difﬁ-
ult to achieve and sustain over the long term. This study also may
nclude such a clinical aspect of a ﬁsh-based diet.
Fish are the major food source of EPA and DHA. The magnitude
f increase in plasma PUFA level following 6-month ﬁsh-based dietiology 63 (2014) 211–217
differed markedly between plasma EPA and DHA in the present
study. We  do not know why plasma DHA level did not signiﬁcantly
increase by a 6-month ﬁsh-based diet in contrast with plasma EPA
level. Regarding changes in plasma omega-3 PUFA, Kondo et al.
also reported that the increase in plasma EPA level was greater
than the increase in plasma DHA level following an 8-week ﬁsh-
based diet in healthy Japanese [27]. Metherel et al. reported that
intake of EPA (3.2 g, together with DHA 1.6 g) resulted in a rapid
increase of plasma EPA in one week after the start of oral ingestion
and smaller change in plasma DHA level [28]. In the OCEAN Study,
the analysis of changes in the composition of fatty acids in carotid
artery plaques following administration of omega-3 PUFA prepa-
ration revealed increased percentage of EPA and no change in the
percentage of DHA [29]. In the present study, the plasma DHA level
in patients with more frequency of ﬁsh intake was higher than that
in patients with less frequency of ﬁsh intake, and the 6-month ﬁsh-
based diet did not result in signiﬁcant increment of plasma DHA.
Those results suggested that the plasma DHA level may  not reﬂect
short-term dietary ﬁsh intake and may  reﬂect long-term dietary
intake.
Ethnic differences in plasma EPA level are known; Japanese peo-
ple have been reported to have higher plasma EPA levels than
Caucasians [30]. However, the percentage occupied by EPA among
all fatty acids ingested has been decreasing in recent years in Japan.
In the present study, plasma EPA/AA ratio was lower than the level
reported from the diet survey in the Kumihama region (mercantile
area 0.58, farming area 0.60, ﬁshing area 0.74) [31].
Conventionally, the assessment of whether the effect of omega-
3 PUFA on CVD events according to dietary intake of omega-3
PUFA was  based on the use of a dietary questionnaire [8,9,23,24]
rather than measurement of plasma PUFA levels [6,13,14,22]. Most
studies of the relationship between ﬁsh intake, omega-3 PUFA
intake, or omega-3 PUFA status and CAD have focused on mortal-
ity [6,8,9,14,22–24]. Our ﬁndings indicate the relationship between
increased baPWV and the change in plasma EPA/AA ratio, and sug-
gested that the increment of plasma EPA/AA ratio might regulate
the accelerated baPWV as a surrogate maker for CVD. The close
attention to plasma EPA/AA ratio could be needed as “a marker for
the residual risk” especially in CAD and high-risk patients.
Study limitations
First, the present ﬁndings were based on a single-center study,
and the sample size was small, in particular, with administration
of pure EPA.
The second limitation was  that baPWV can depend on various
factors such as age, SBP, blood glucose, vascular stenosis, exercise,
and lifestyle management [32–34]. The third limitation pertains to
adherence to a 6-month ﬁsh-based diet. This study may  reﬂect not
only the effect of a ﬁsh-based diet but also the outcome of adher-
ence to a daily intake of ﬁsh. The fourth limitation pertains to the
lack of the control group in comparison with the EPA intervention
group. With regard to this, we  examined by the comparison of after
ﬁsh-based diet and after sequential treatment with pure EPA.
Therefore, it seems necessary to carry out additional studies
with these limitations.
Conclusions
The present ﬁndings revealed a beneﬁcial effect of a ﬁsh-basedity of more aggressive treatment, pure EPA (1800 mg/day) in CAD
and high-risk patients for preventing progression of baPWV. This
study thus endorsed the validity of high purity EPA administration
recommended in the current guidelines.
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